Avalo CEO awarded 100,200 performance shares
Avalo Therapeutics’ CEO Neil Garry Arthur received a large equity award tied to performance.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Avalo Therapeutics’ CEO Neil Garry Arthur received a large equity award tied to performance. He was granted 100,200 shares of Common Stock as a grant/award acquisition at a price of $0.00 per share, increasing his direct holdings to 190,314 shares.
According to the footnote, this represents performance stock units granted on August 19, 2025. Each unit converts into one share only if specific performance goals are met. The Compensation Committee certified achievement of those goals on May 21, 2026, and the shares are scheduled to fully vest on August 19, 2028, if he remains in service.
Insider Trade Summary
Grant/Award: 100,200 shares
Grant/Award
1 txn
Insider
NEIL GARRY ARTHUR
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 100,200 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 190,314 shares (Direct)
Footnotes (1)
- F1. Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.
Key Figures
Shares granted: 100,200 shares
Price per share: $0.00 per share
Total holdings after transaction: 190,314 shares
+3 more
6 metrics
Shares granted
100,200 shares
Grant/award acquisition on May 21, 2026
Price per share
$0.00 per share
Grant/award acquisition of Common Stock
Total holdings after transaction
190,314 shares
Direct ownership after Form 4 transaction
PSU grant date
August 19, 2025
Performance stock units originally granted
Performance certification date
May 21, 2026
Compensation Committee certified performance goals
Vesting date
August 19, 2028
Shares scheduled to fully vest
Key Terms
performance stock units, PSUs, Compensation Committee, vest
4 terms
performance stock units financial
"Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025."
Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.
PSUs financial
"Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025."
PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.
Compensation Committee financial
"On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals."
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
vest financial
"the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Avalo Therapeutics (AVTX) disclose about its CEO’s recent equity award?
Avalo Therapeutics reported that CEO Neil Garry Arthur received 100,200 shares of Common Stock as a grant/award acquisition at $0.00 per share, bringing his direct holdings to 190,314 shares after the transaction, according to the Form 4 insider filing.
What are the terms of the Avalo Therapeutics (AVTX) CEO performance stock units?
The CEO’s award represents performance stock units granted on August 19, 2025. Each unit gives a right to one share of Common Stock if specified performance goals are met, with the shares scheduled to fully vest on August 19, 2028, subject to continued service.
When were performance goals for Avalo Therapeutics (AVTX) CEO’s PSUs certified?
Avalo Therapeutics’ Compensation Committee certified achievement of the performance goals for the CEO’s performance stock units on May 21, 2026. This certification triggers the vesting schedule that runs until August 19, 2028, assuming the CEO continues in service.
Is the Avalo Therapeutics (AVTX) CEO’s recent equity award an immediate cash transaction?
No, the CEO’s reported grant shows a price of $0.00 per share and represents performance stock units. These units convert to shares only upon performance certification and will fully vest on August 19, 2028, subject to the CEO’s continued service with Avalo Therapeutics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
